ofloxacin has been researched along with Infections, Respiratory in 186 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Prulifloxacin is as effective and well tolerated as levofloxacin in the treatment of respiratory and urinary tract infections." | 9.16 | Prulifloxacin versus levofloxacin in the treatment of respiratory and urinary tract infections: a multicentre, double-blind, randomized controlled clinical trial. ( Chen, Y; Huang, W; Li, Q; Lu, G; Lv, X; Sun, Y; Wu, G; Wu, X; Wu, Y; Yang, H; Zhang, G, 2012) |
| "The purpose of the study was to assess the bactericidal effects of a single oral dose of levofloxacin (LVFX) by examining the concentration of LVFX in alveolar epithelial lining fluid (ELF) from patients with lower respiratory tract infections (LRTI)." | 9.14 | Permeability and concentration of levofloxacin in epithelial lining fluid in patients with lower respiratory tract infections. ( Cao, GY; Chen, YQ; Shi, YG; Wu, XJ; Xie, X; Yu, JC; Zhang, J; Zhang, YY; Zhou, X, 2010) |
| "The efficacy and tolerance of ofloxacin and doxycycline were compared in patients with lower respiratory tract infections." | 9.06 | An open randomised comparison of ofloxacin and doxycycline in lower respiratory tract infections. ( Harazim, H; Mittermayer, HP; Wimmer, J, 1987) |
| "A multicentre clinical trial was carried out to determine the activity and tolerability of ofloxacin in the treatment of lower respiratory tract infections." | 9.06 | Clinical efficacy of ofloxacin in lower respiratory tract infections. A multicentre study. ( Gialdroni Grassi, G; Grassi, C; Mangiarotti, P, 1987) |
| "An open study was conducted in 40 randomized patients to evaluate the efficacy of ofloxacin in comparison with cefazolin in the treatment of acute, chronic and recurrent lower respiratory tract infections." | 9.06 | A comparative study of ofloxacin versus cefazolin in lower respiratory tract infections. ( Bariffi, F; De Masi, AL; Giacomelli, P; Perna, F; Sanduzzi, A, 1987) |
| "Limited data suggest that tetracycline or erythromycin is the antibiotic of choice for treating Chlamydia pneumoniae infection, but they are not always effective or well tolerated." | 9.06 | Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections. ( Grayston, JT; Kuo, CC; Lipsky, BA; Tack, KJ; Wang, SP, 1990) |
| "A multicenter trial on the efficacy and tolerability of ofloxacin in upper and lower respiratory tract infections and urinary tract infections was carried out on 1,436 patients (926 males and 510 females; mean age 55." | 9.06 | A multicenter study on clinical efficacy of ofloxacin in respiratory and urinary tract infections. ( Grassi, GG, 1986) |
| "32 hospitalized adult patients with infective episodes of bronchiectasis were enrolled in an ongoing double-blind, placebo-controlled study comparing ofloxacin with amoxicillin." | 9.06 | A double-blind randomized study comparing ofloxacin and amoxicillin in treating infective episodes in bronchiectasis. ( Chan, JC; Chau, PY; Lam, WK; Leung, YK; Sham, MK; So, SY, 1986) |
| "In an open clinical trial, out-patients with respiratory tract infections were given 200 mg ofloxacin b." | 9.06 | [Respiratory tract infections--clinical results with ofloxacin]. ( Knothe, H; Shah, PM, 1986) |
| "Levofloxacin is considered an effective antibiotic in the treatment of community-acquired lower respiratory tract infections (LRTIs)." | 7.72 | Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. ( Brollo, L; Di Qual, E; Dolcet, F; Furlanut, M; Lugatti, E; Pea, F; Talmassons, G, 2003) |
| "The influence of patient relevant parameters such as age, comorbidity, or duration of disease on the treatment success of levofloxacin for community-acquired respiratory tract infections (CARTI) has not been thoroughly elucidated." | 7.72 | The influence of comorbidity on the effect of levofloxacin treatment success of ambulatory respiratory tract infections. ( Burgmann, H; Kumbein, F; Lukas, A; Mayer, B; Oberbauer, R, 2003) |
| "The appropriate administration method of levofloxacin in relation to symptoms was investigated by following up 2,353 patients prescribed either levofloxacin (300 mg divided into 3 doses) or 400 mg (divided into 2 doses) for the treatment of acute upper respiratory tract infection accompanied by fever (temperature (> or = 38 degrees C) of suspected bacterial infection." | 7.72 | [Use of the antibacterial agent levofloxacin for acute upper respiratory tract infection accompanied by fever (> or = 38 degrees C)]. ( Matsumoto, T; Odagiri, S; Uchino, K; Yamaguchi, H; Yokoyama, H, 2003) |
| "Forty patients were treated with ofloxacin for community acquired lower respiratory tract infections." | 7.70 | Intravenous followed by oral ofloxacin in the treatment of community acquired lower respiratory tract infections in adults requiring hospitalisation. ( Aziah, AM; Liam, CK; Lim, KH; Wong, CM, 2000) |
| "Two different oral ofloxacin regimens, a daily single-dose regimen with 200 mg (Regimen I) and an every-two-week multidose regimen with 3 x 200 mg/day (Regimen II) was compared as to the efficacy in controlling repeated acute exacerbations of chronic respiratory tract infections." | 7.69 | Daily single-dose regimen and alternate-two-week triple-dose/day regimen of oral ofloxacin for the prophylaxis and control of exacerbations of chronic respiratory tract infections. ( Motomiya, M; Nukiwa, T; Oizumi, K; Watanabe, A, 1995) |
| "The aim of the study was to analyse the clinical effectiveness of ofloxacin in treatment of post-infectious exacerbations of endogenous bronchial asthma." | 7.68 | [Clinical analysis of ofloxacin in treatment of postinfectious exacerbations of endogenous bronchial asthma]. ( Frank-Piskorska, A; Józefczak, E; Kałczak, M; Płusa, T, 1993) |
| "The clinical efficacy and the safety of ofloxacin in lower respiratory tract infections were evaluated by 42 research groups in Japan." | 7.67 | Clinical evaluation of ofloxacin in lower respiratory tract infections. ( Kobayashi, H, 1986) |
| "General practitioners assessed the efficacy and safety of ofloxacin in the treatment of lower respiratory tract infections in 100 patients." | 7.67 | Efficacy of ofloxacin in the treatment of lower respiratory tract infections in general practice. ( Clarke, PC; Moorhouse, EC, 1988) |
| " This study concluded that the dosage regimen of LVFX 500 mg once daily was effective and tolerable for the treatment of LRTIs and UTIs." | 6.74 | Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China. ( Chen, BY; Ding, GH; Duan, J; Gu, JM; Guo, DY; Hao, QL; Huang, HH; Huang, JA; Li, HY; Li, QH; Liu, A; Lü, XJ; Ma, H; Ren, ZY; Shen, HH; Shi, MH; Si, B; Sun, SH; Sun, TY; Wu, GM; Xia, QM; Xiao, W; Xiao, ZK; Xiu, QY; Yang, HF; Yang, HP; Yao, WZ; Ying, KJ; Yu, YS; Yue, HM; Zhang, W; Zhang, YY; Zheng, HG, 2009) |
| "Forty patients with chronic respiratory infections were randomly assigned to 2 groups to compare the effect of once daily administration of 300 mg each and 3 times daily administration of 600 mg each of ofloxacin (OFLX)." | 6.67 | [Clinical studies of ofloxacin 300 mg once a day administration in chronic respiratory tract infections]. ( Fukuhara, H; Horimoto, S; Inadame, J; Irabu, Y; Kusano, N; Miyagi, M; Nakamura, H; Saito, A; Shigeno, Y; Shimozi, T, 1993) |
| "Ofloxacin was usually administered as a 200 mg dose bd." | 6.67 | A comparative study of ofloxacin and amoxycillin/clavulanate in hospitalized patients with lower respiratory tract infections. ( Drlicek, M; Khajotia, R; Vetter, N, 1990) |
| " 29 patients started ofloxacin treatment with a dosage of 200 mg or 300 mg b." | 6.66 | Ofloxacin in lower respiratory tract infections--a comparison with amoxicillin. ( Devogelaere, R; Maes, P, 1986) |
| "Levofloxacin is a valuable antimicrobial agent and an optimal treatment option for AECB, CAP (as a monotherapy) and HAP (as combination therapy at a high-dose regimen)." | 6.48 | Levofloxacin for the treatment of respiratory tract infections. ( Liapikou, A; Torres, A, 2012) |
| " The oral bioavailability of levofloxacin is over 99%, enabling simple switching from intravenous to oral therapy during treatment." | 6.43 | Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin. ( Cantón, R; Graninger, W; Lode, H; Milkovich, G, 2006) |
| "Levofloxacin is a second generation fluoroquinolone with a post marketing history of well tolerated and successful use in a variety of clinical situations." | 6.41 | A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections. ( Garvin, CG; Jung, R; Martin, SJ, 2001) |
| " The lung tissue penetration of ofloxacin after a dosage of 200 mg twice daily, reached a mean tissue plasma concentration ratio of 3." | 6.38 | Ofloxacin concentrations in tissues involved in respiratory tract infections. ( Perea, EJ, 1990) |
| " In therapy of chronic diseases exacerbations of the respiratory tract, including community-acquired pneumonia, a high oral bioavailability allows to switch from intravenous to oral way of treatment." | 5.37 | [Levofloxacin and other fluoroquinolones in therapy of respiratory tract infections]. ( Płusa, T, 2011) |
| "Ciprofloxacin was the most active compound against Pseudomonas aeruginosa (MIC90 = 1 mg/L), followed by trovafloxacin (MIC90 = 4 mg/L)." | 5.30 | In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections. ( Hoogkamp-Korstanje, JA, 1997) |
| "Prulifloxacin is as effective and well tolerated as levofloxacin in the treatment of respiratory and urinary tract infections." | 5.16 | Prulifloxacin versus levofloxacin in the treatment of respiratory and urinary tract infections: a multicentre, double-blind, randomized controlled clinical trial. ( Chen, Y; Huang, W; Li, Q; Lu, G; Lv, X; Sun, Y; Wu, G; Wu, X; Wu, Y; Yang, H; Zhang, G, 2012) |
| "The purpose of the study was to assess the bactericidal effects of a single oral dose of levofloxacin (LVFX) by examining the concentration of LVFX in alveolar epithelial lining fluid (ELF) from patients with lower respiratory tract infections (LRTI)." | 5.14 | Permeability and concentration of levofloxacin in epithelial lining fluid in patients with lower respiratory tract infections. ( Cao, GY; Chen, YQ; Shi, YG; Wu, XJ; Xie, X; Yu, JC; Zhang, J; Zhang, YY; Zhou, X, 2010) |
| "The efficacy and safety of oral ofloxacin, 400 mg once daily, for the treatment of patients with lower respiratory tract infections were studied." | 5.07 | Clinical studies of oral quinolone once daily in the treatment of lower respiratory tract infections. ( Fujino, K; Ichikawa, Y; Kawahara, M; Oizumi, K; Ouchi, K; Rikimaru, T; Shima, R; Tanaka, F; Yano, T, 1993) |
| "Two different oral ofloxacin regimens, daily single-dose treatment with 200 mg (Regimen I) and every two week multidose treatment with 3 x 200 mg/day (Regimen II), were compared to evaluate the efficacy of quinolone regimens in controlling acute exacerbations of chronic respiratory tract infections." | 5.07 | Once daily versus every two week multidose ofloxacin in patients with acute exacerbations of chronic respiratory disease. ( Watanabe, A, 1991) |
| "To assess the safety and efficacy of a ten-day oral course of ofloxacin (400 mg 12 hourly) as compared with erythromycin (400 mg every 6 hours) for treatment of lower respiratory tract infections, fifty-two adult outpatients with pulmonary infiltrates (pneumonia) or with a cough and purulent sputum (bronchitis) were evaluated." | 5.07 | Treatment of lower respiratory infections in outpatients with ofloxacin compared with erythromycin. ( Hooton, TM; Lipsky, BA; Pecoraro, RE; Peugeot, RL, 1991) |
| "A multicentre clinical trial was carried out to determine the activity and tolerability of ofloxacin in the treatment of lower respiratory tract infections." | 5.06 | Clinical efficacy of ofloxacin in lower respiratory tract infections. A multicentre study. ( Gialdroni Grassi, G; Grassi, C; Mangiarotti, P, 1987) |
| "An open clinical study of ofloxacin in respiratory tract infections was conducted with patients receiving daily doses of ofloxacin 300 mg, 400 mg or 600 mg." | 5.06 | Ofloxacin in respiratory tract infection. A review of the results of clinical trials in Japan. ( Katsu, M; Saito, A; Soejima, R, 1987) |
| "An open study was conducted in 40 randomized patients to evaluate the efficacy of ofloxacin in comparison with cefazolin in the treatment of acute, chronic and recurrent lower respiratory tract infections." | 5.06 | A comparative study of ofloxacin versus cefazolin in lower respiratory tract infections. ( Bariffi, F; De Masi, AL; Giacomelli, P; Perna, F; Sanduzzi, A, 1987) |
| "The efficacy and tolerance of ofloxacin and doxycycline were compared in patients with lower respiratory tract infections." | 5.06 | An open randomised comparison of ofloxacin and doxycycline in lower respiratory tract infections. ( Harazim, H; Mittermayer, HP; Wimmer, J, 1987) |
| "In an open clinical trial, out-patients with respiratory tract infections were given 200 mg ofloxacin b." | 5.06 | [Respiratory tract infections--clinical results with ofloxacin]. ( Knothe, H; Shah, PM, 1986) |
| "32 hospitalized adult patients with infective episodes of bronchiectasis were enrolled in an ongoing double-blind, placebo-controlled study comparing ofloxacin with amoxicillin." | 5.06 | A double-blind randomized study comparing ofloxacin and amoxicillin in treating infective episodes in bronchiectasis. ( Chan, JC; Chau, PY; Lam, WK; Leung, YK; Sham, MK; So, SY, 1986) |
| "Ofloxacin is highly active against common respiratory pathogens including Haemophilus influenzae and Branhamella catarrhalis and has clinically applicable activity against Streptococcus pneumoniae, Staphylococcus aureus and Pseudomonas aeruginosa." | 5.06 | Overview of experience with ofloxacin in respiratory tract infection. ( Ball, P, 1990) |
| "A multicenter trial on the efficacy and tolerability of ofloxacin in upper and lower respiratory tract infections and urinary tract infections was carried out on 1,436 patients (926 males and 510 females; mean age 55." | 5.06 | A multicenter study on clinical efficacy of ofloxacin in respiratory and urinary tract infections. ( Grassi, GG, 1986) |
| "Thirteen hospitalized patients with various infections, five with typhoid fever, two with gastroenteritis, four with respiratory tract infection and two with biliary tract infection, were treated with ofloxacin at a daily dosage ranging between 600 and 900 mg orally." | 5.06 | Clinical experience with ofloxacin (DL 8280) in the therapy of various infections: preliminary report. ( Altucci, P; Briante, V; Cristiano, P; Leonessa, V; Morelli, G; Paradisi, F, 1986) |
| "Limited data suggest that tetracycline or erythromycin is the antibiotic of choice for treating Chlamydia pneumoniae infection, but they are not always effective or well tolerated." | 5.06 | Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections. ( Grayston, JT; Kuo, CC; Lipsky, BA; Tack, KJ; Wang, SP, 1990) |
| "Significant associations between levofloxacin use and influenza rates, after accounting for season, may suggest that levofloxacin was used to treat secondary bacterial infections or was prescribed inappropriately for seasonal viral respiratory tract infections." | 3.76 | A province-level risk factor analysis of fluoroquinolone consumption patterns in Canada (2000-06). ( Finley, R; Glass, SK; McEwen, SA; Pearl, DL, 2010) |
| "In vitro evidence of synergy between glycopeptides, fluoroquinolones (levofloxacin) and beta-lactams and of reduction of mutational frequencies by combinations are suggestive for a potential role in empirical therapy of severe pneumonia with suspected MRSA etiology." | 3.74 | In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections. ( De Vecchi, E; Drago, L; Gismondo, MR; Nicola, L, 2007) |
| "Levofloxacin is considered an effective antibiotic in the treatment of community-acquired lower respiratory tract infections (LRTIs)." | 3.72 | Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. ( Brollo, L; Di Qual, E; Dolcet, F; Furlanut, M; Lugatti, E; Pea, F; Talmassons, G, 2003) |
| "The influence of patient relevant parameters such as age, comorbidity, or duration of disease on the treatment success of levofloxacin for community-acquired respiratory tract infections (CARTI) has not been thoroughly elucidated." | 3.72 | The influence of comorbidity on the effect of levofloxacin treatment success of ambulatory respiratory tract infections. ( Burgmann, H; Kumbein, F; Lukas, A; Mayer, B; Oberbauer, R, 2003) |
| "The administration of levofloxacin to patients with ESRD as 500 mg initially, followed by 250 mg every 48 hours, will provide adequate C(max)-MIC ratios after the first and subsequent doses for most patients with respiratory tract infections caused by organisms with levofloxacin MICs of 1 microg/mL or less." | 3.72 | Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer. ( Hamburger, RJ; Kays, MB; Lucksiri, A; Mueller, BA; Scott, MK; Sowinski, KM, 2003) |
| "The appropriate administration method of levofloxacin in relation to symptoms was investigated by following up 2,353 patients prescribed either levofloxacin (300 mg divided into 3 doses) or 400 mg (divided into 2 doses) for the treatment of acute upper respiratory tract infection accompanied by fever (temperature (> or = 38 degrees C) of suspected bacterial infection." | 3.72 | [Use of the antibacterial agent levofloxacin for acute upper respiratory tract infection accompanied by fever (> or = 38 degrees C)]. ( Matsumoto, T; Odagiri, S; Uchino, K; Yamaguchi, H; Yokoyama, H, 2003) |
| "The in vitro activity of moxifloxacin was compared with that of ciprofloxacin, levofloxacin, ofloxacin and trovafloxacin against 710 strains (180 Streptococcus pneumoniae, 180 Haemophilus influenzae, 160 Moraxella catarrhalis and 190 Streptococcus pyogenes) isolated from patients with community-acquired respiratory tract infections." | 3.71 | Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens. ( Ambler, J; Cardeñosa, O; Lemme, L; Lopez, H; Scarano, S; Smayevsky, J; Stepanik, D; Sucari, A; Vilches, V, 2001) |
| "Forty patients were treated with ofloxacin for community acquired lower respiratory tract infections." | 3.70 | Intravenous followed by oral ofloxacin in the treatment of community acquired lower respiratory tract infections in adults requiring hospitalisation. ( Aziah, AM; Liam, CK; Lim, KH; Wong, CM, 2000) |
| "When seven elderly patients with fever due to bacterial infection failed to respond to ofloxacin 300 mg/day for 3 days, we prescribed Mao-bushi-saishin-to for 7 days." | 3.70 | Effect of Mao-bushi-saishin-to on infection of ofloxacin resistant bacteria and of unknown origin. ( Kamei, T; Tomioka, H; Toriumi, Y, 2000) |
| "This paper reports the pharmacokinetic characteristics of ofloxacin (Ofl) through 3 administration routes in 42 patients with respiratory tract infections." | 3.69 | Pharmacokinetics of ofloxacin through three administration routes. ( Ling, SS; Lu, JZ; Xia, XR; Zhuo, HT, 1994) |
| "Two different oral ofloxacin regimens, a daily single-dose regimen with 200 mg (Regimen I) and an every-two-week multidose regimen with 3 x 200 mg/day (Regimen II) was compared as to the efficacy in controlling repeated acute exacerbations of chronic respiratory tract infections." | 3.69 | Daily single-dose regimen and alternate-two-week triple-dose/day regimen of oral ofloxacin for the prophylaxis and control of exacerbations of chronic respiratory tract infections. ( Motomiya, M; Nukiwa, T; Oizumi, K; Watanabe, A, 1995) |
| "The effects of orally administered ofloxacin on functional parameters of cell-mediated immunity were investigated in 15 patients with respiratory or urinary tract infections." | 3.68 | Effects of ofloxacin on cell-mediated immune response and lymphokine production. ( Arpinelli, F; Benedetti, M; Biglino, A; Busso, M; Forno, B; Pollono, AM; Pugliese, A, 1990) |
| "The aim of the study was to analyse the clinical effectiveness of ofloxacin in treatment of post-infectious exacerbations of endogenous bronchial asthma." | 3.68 | [Clinical analysis of ofloxacin in treatment of postinfectious exacerbations of endogenous bronchial asthma]. ( Frank-Piskorska, A; Józefczak, E; Kałczak, M; Płusa, T, 1993) |
| "The clinical efficacy and the safety of ofloxacin in lower respiratory tract infections were evaluated by 42 research groups in Japan." | 3.67 | Clinical evaluation of ofloxacin in lower respiratory tract infections. ( Kobayashi, H, 1986) |
| " It was used alone 26 times and on 6 occasions it was associated with rifampin on 6 staphylococcal infections." | 3.67 | [Ofloxacin (RU 43280). Clinical study]. ( Bertrand, A; Despaux, E; Janbon, F; Jonquet, O; Reynes, J, 1987) |
| "The therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 was compared in alloxan-induced diabetic mice with experimental respiratory and urinary tract infections." | 3.67 | Therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 in experimentally infected normal and alloxan-induced diabetic mice. ( Nishino, T; Obana, Y, 1988) |
| "Thirty-four hospitalized patients with various infections: 19 with typhoid fever, 4 with gastroenteritis, 7 with lower respiratory tract infections, 2 with biliary tract infections, 1 with brucellosis and 1 with infection of necrotic ulceration of the feet, were treated with ofloxacin at a daily dosage ranging between 600 and 900 mg orally." | 3.67 | Clinical experience with ofloxacin (DL-8280) in the therapy of various infections. ( Altucci, P; Cristiano, P; Iovene, MR; Mandia, L; Morelli, G; Paradisi, F, 1989) |
| "General practitioners assessed the efficacy and safety of ofloxacin in the treatment of lower respiratory tract infections in 100 patients." | 3.67 | Efficacy of ofloxacin in the treatment of lower respiratory tract infections in general practice. ( Clarke, PC; Moorhouse, EC, 1988) |
| " This study concluded that the dosage regimen of LVFX 500 mg once daily was effective and tolerable for the treatment of LRTIs and UTIs." | 2.74 | Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China. ( Chen, BY; Ding, GH; Duan, J; Gu, JM; Guo, DY; Hao, QL; Huang, HH; Huang, JA; Li, HY; Li, QH; Liu, A; Lü, XJ; Ma, H; Ren, ZY; Shen, HH; Shi, MH; Si, B; Sun, SH; Sun, TY; Wu, GM; Xia, QM; Xiao, W; Xiao, ZK; Xiu, QY; Yang, HF; Yang, HP; Yao, WZ; Ying, KJ; Yu, YS; Yue, HM; Zhang, W; Zhang, YY; Zheng, HG, 2009) |
| "Grepafloxacin was highly active against Gram-negative organisms and adequate against pneumococci (mean, 1:13." | 2.70 | Crossover assessment of serum bactericidal activity of grepafloxacin, ofloxacin and clarithromycin against respiratory pathogens after oral administration to healthy volunteers. ( Asherov, J; Dan, M; Poch, F, 2001) |
| " This pharmacokinetic modeling could be used to determine optimal treatment dose in clinical trials in a shorter time frame with fewer patients." | 2.69 | Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. ( Berman, AL; Chow, AT; Corrado, M; Dornseif, B; Drusano, GL; Fowler, CL; Natarajan, J; Preston, SL; Reichl, V, 1998) |
| "Ofloxacin was usually administered as a 200 mg dose bd." | 2.67 | A comparative study of ofloxacin and amoxycillin/clavulanate in hospitalized patients with lower respiratory tract infections. ( Drlicek, M; Khajotia, R; Vetter, N, 1990) |
| "Ofloxacin treatment was used for the treatment of lower respiratory tract infections in 35 patients." | 2.67 | Severe infections treated with intravenous ofloxacin: a prospective clinical multicentre Swiss study. ( Regamey, C; Steinbach-Lebbin, C, 1990) |
| "Forty patients with chronic respiratory infections were randomly assigned to 2 groups to compare the effect of once daily administration of 300 mg each and 3 times daily administration of 600 mg each of ofloxacin (OFLX)." | 2.67 | [Clinical studies of ofloxacin 300 mg once a day administration in chronic respiratory tract infections]. ( Fukuhara, H; Horimoto, S; Inadame, J; Irabu, Y; Kusano, N; Miyagi, M; Nakamura, H; Saito, A; Shigeno, Y; Shimozi, T, 1993) |
| "Ofloxacin therapy was administered an average of 45 days per patient, and was well tolerated." | 2.67 | Oral ofloxacin for infections caused by bacteria resistant to oral antimicrobial agents. ( Eron, LJ; Gentry, LO, 1992) |
| "Ofloxacin was used without randomization in the treatment of 26 atypical pneumonias and opportunistic infections, all of which were cured or improved." | 2.66 | [Effect and tolerance of ofloxacin in bronchopulmonary infections in comparison with amoxicillin]. ( Chuard, C; Regamey, C, 1989) |
| "Ofloxacin was found to be a safe, well-tolerated therapeutic agent, which was as effective clinically as amoxicillin or erythromycin and with an advantage of less frequent administration." | 2.66 | Ofloxacin in community-acquired lower respiratory infections. A comparison with amoxicillin or erythromycin. ( Garcia, JG; Griffith, DE; Kohler, RB; Stocks, JM; Wallace, RJ, 1989) |
| " 29 patients started ofloxacin treatment with a dosage of 200 mg or 300 mg b." | 2.66 | Ofloxacin in lower respiratory tract infections--a comparison with amoxicillin. ( Devogelaere, R; Maes, P, 1986) |
| "Ofloxacin proved to be an effective and well-tolerated substance." | 2.66 | Clinical experience with ofloxacin in upper and lower urinary tract infections. A comparison with co-trimoxazole and nitrofurantoin. ( Ludwig, G; Pauthner, H, 1987) |
| "Ofloxacin is a new quinolone-carboxylic acid derivative with a broad spectrum of activity, excellent bioavailability after oral administration and insignificant metabolisation." | 2.66 | [Summarized results of clinical phase II and III studies with ofloxacin (HOE 280) in Europe]. ( Blomer, R; Bruch, K; Zahlten, RN, 1986) |
| "Levofloxacin is a valuable antimicrobial agent and an optimal treatment option for AECB, CAP (as a monotherapy) and HAP (as combination therapy at a high-dose regimen)." | 2.48 | Levofloxacin for the treatment of respiratory tract infections. ( Liapikou, A; Torres, A, 2012) |
| " In particular, the deeper knowledge of kinetic-dynamic characteristics has allowed to highlight that high dosage approach in short term therapy might reveal as extremely interesting in a setting of critical patients." | 2.45 | [PK/PD profile and post-marketing surveillance of levofloxacin]. ( Pea, F, 2009) |
| " The oral bioavailability of levofloxacin is over 99%, enabling simple switching from intravenous to oral therapy during treatment." | 2.43 | Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin. ( Cantón, R; Graninger, W; Lode, H; Milkovich, G, 2006) |
| "We compared adverse event data for levofloxacin 500 mg and 750 mg from clinical trials in acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and community-acquired pneumonia." | 2.43 | Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections. ( Kahn, JB; Khashab, MM; Xiang, J, 2006) |
| "Levofloxacin is a second generation fluoroquinolone with a post marketing history of well tolerated and successful use in a variety of clinical situations." | 2.41 | A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections. ( Garvin, CG; Jung, R; Martin, SJ, 2001) |
| "Pharmacokinetic characteristics and pharmacodynamic properties dictate antimicrobial response and, along with natural immune responses, clinical outcomes." | 2.41 | What have we learned from pharmacokinetic and pharmacodynamic theories? ( Gilliland, KK; Paladino, JA; Schentag, JJ, 2001) |
| "Oral levofloxacin was also similar in efficacy to amoxicillin/clavulanic acid or oral clarithromycin in patients with acute maxillary sinusitis treated for 7 to 14 days." | 2.40 | Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. ( Lamb, HM; Langtry, HD, 1998) |
| "Levofloxacin has a tolerability profile similar to that of other oral fluoroquinolones, with gastrointestinal and central nervous system effects reported most commonly." | 2.39 | Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. ( Bryson, HM; Davis, R, 1994) |
| " The lung tissue penetration of ofloxacin after a dosage of 200 mg twice daily, reached a mean tissue plasma concentration ratio of 3." | 2.38 | Ofloxacin concentrations in tissues involved in respiratory tract infections. ( Perea, EJ, 1990) |
| "Levofloxacin was administered daily beginning at 6 to 12 h postexposure for 7 treatments." | 1.38 | Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax. ( Bourdage, JS; Duchars, M; Fuerst, TR; Fusco, PC; Leffel, EK; Williamson, ED, 2012) |
| " In therapy of chronic diseases exacerbations of the respiratory tract, including community-acquired pneumonia, a high oral bioavailability allows to switch from intravenous to oral way of treatment." | 1.37 | [Levofloxacin and other fluoroquinolones in therapy of respiratory tract infections]. ( Płusa, T, 2011) |
| "aeruginosa from respiratory tract infections at 13-21%, which was the same trend as in past years." | 1.35 | [In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,919 clinical isolates obtained from 72 centers in 2007]. ( Aihara, M; Akiyama, T; Akizawa, K; Aoki, Y; Asano, Y; Baba, H; fujimoto, Y; Fujita, J; Fujita, S; Fujiwara, H; Genma, H; Gonda, H; Haruki, K; Hashikita, G; Hayashi, M; Heijyou, H; Hida, Y; Hiramatsu, K; Horiuchi, H; Ichiyama, S; Idomuki, M; Ieiri, T; Ikeda, N; Inuzuka, K; Iriyama, J; Ishii, Y; Ito, T; Iwata, M; Kaku, M; Kamioka, M; Kanda, M; Kang, D; Kanno, H; Katayama, Y; Kato, J; Kawahara, K; Kawamura, C; Kawano, S; Kawashima, C; Kinoshita, S; Kobayashi, Y; Kohno, S; Koike, K; Kon, S; Kondou, S; Kono, H; Kumasaka, K; Kusaba, K; Kusakabe, T; Kusano, N; Kuwabara, M; Maekawa, M; Maesaki, S; Masaki, H; Mashiba, K; Matsuda, J; Matsuda, K; Matsuo, S; Miki, M; Misawa, S; Miyajima, E; Miyanohara, H; Moro, K; Murakami, M; Murase, M; Murata, M; Nagai, A; Nakagawa, T; Nakamura, K; Nakashima, Y; Nakasone, I; Nakatani, K; Nakaya, H; Negayama, K; Ohno, A; Oka, M; Okabe, H; Okada, M; Okamoto, H; Okamoto, Y; Okayama, A; Okazaki, T; Okubo, S; Ono, J; Ota, H; Ozaki, Y; Saikawa, T; Saito, T; Sano, R; Sekine, I; Shigeta, M; Shimizu, C; Shiotani, J; Soma, M; Sugita, A; Sugiura, T; Sumitomo, M; Suwabe, A; Takubo, T; Taniguchi, N; Tashiro, H; Tateda, K; Tazawa, Y; Tominaga, M; Toyoshima, S; Uchida, T; Yamaguchi, I; Yamaguchi, K; Yamahata, K; Yamamoto, G; Yamamoto, Y; Yamane, N; Yamashita, M; Yamazaki, K; Yanagihara, K; Yasujima, M; Yoneyama, A; Yoshida, H; Yoshimura, H; Yuzuki, Y, 2009) |
| "Levofloxacin resistance was detected in 2 of 2,834 isolates (0." | 1.32 | Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. ( Critchley, IA; Evangelista, AT; Jones, ME; Karlowsky, JA; Noel, GJ; Sahm, DF; Thornsberry, C, 2003) |
| "Gatifloxacin was the most active against P." | 1.32 | Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections. ( Daschner, F; Schmidt-Eisenlohr, E; Wenzler, S, 2004) |
| "Levofloxacin was predominantly prescribed for treating community-acquired infections (67." | 1.32 | [Observational study investigating the use of levofloxacin in ICU patients]. ( Alvarez-Lerma, F; Bermejo, B; León, C; Olaechea, P; Palomar, M; Sánchez, M, 2004) |
| "Levofloxacin resistance was rarely associated with MDR phenotypes." | 1.32 | The activity of levofloxacin and other antimicrobials against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999-2002. ( Blosser-Middleton, RS; Jones, ME; Karlowsky, JA; Sahm, DF; Thornsberry, C, 2003) |
| "Ciprofloxacin was the most active compound against Pseudomonas aeruginosa (MIC90 = 1 mg/L), followed by trovafloxacin (MIC90 = 4 mg/L)." | 1.30 | In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections. ( Hoogkamp-Korstanje, JA, 1997) |
| "Levofloxacin-induced-neurological adverse events such as convulsion, involuntary movement (tremor, myoclonus and chorea-like) and visual hallucination in two elderly patients are reported." | 1.30 | [Levofloxacin-induced neurological adverse effects such as convulsion, involuntary movement (tremor, myoclonus and chorea like), visual hallucination in two elderly patients]. ( Fukayama, M; Inamatsu, T; Kita, Y; Masuda, Y; Yasuda, H; Yoshida, A, 1999) |
| "Levofloxacin was more active against S." | 1.30 | Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. ( Kahn, J; Mauriz, Y; Ogilvie, P; Thornsberry, C, 1997) |
| "HSR-903 was active against experimental respiratory tract infections in mice challenged with penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae and Haemophilus influenzae strains." | 1.30 | In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens. ( Domon, H; Miyazaki, S; Yamaguchi, K; Yoshizumi, S, 1998) |
| "In the group of the patients with wound infection complicated by respiratory or urinary tract infection the clinical and bacteriological efficacies equaled 94-100 per cent." | 1.29 | [Ten-year experience with the use of ofloxacin in the treatment of wound infection]. ( Blatun, LA; Iakovlev, VP; Izotova, GN; Puchkova, LS; Svetukhin, AM, 1996) |
| "Sparfloxacin was fourfold more active against Staphylococcus aureus and Streptococcus pneumoniae." | 1.29 | In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens. ( Ahlén, S; Malmborg, AS, 1993) |
| "Ofloxacin was determined to have the widest spectrum of activity and potential empiric use (90." | 1.28 | Ofloxacin, a new broad-spectrum fluoroquinolone. Results from a Multicenter, National Comparative Activity Surveillance Study. The Ofloxacin Surveillance Group. ( Erwin, ME; Jones, RN; Reller, LB; Rosati, LA; Sanchez, ML, 1992) |
| " aeruginosa appeared in the cases of long-term administration of OFLX." | 1.28 | [A clinical experience of ofloxacin in patients with respiratory infection]. ( Akisawa, T; Kaneshige, H; Nakagami, K; Narushima, M; Otsuka, H; Shimizu, S; Suzuki, H; Takagi, H; Tanaka, K; Tonotsuka, H, 1989) |
| "Against respiratory tract infections with K." | 1.28 | In vivo evaluation of NM441, a new thiazeto-quinoline derivative. ( Kimura, K; Kise, M; Kitano, M; Matsuda, M; Nishino, T; Otsuki, M; Ozaki, M; Segawa, J; Shibata, K; Tomii, Y, 1991) |
| "Ofloxacin was active against all but one (Pseudomonas aeruginosa) blood culture isolates." | 1.27 | Comparative activity of ofloxacin with reference to bacterial strains isolated in in-patients and out-patients. ( Alkan, M; Berger, S; Bogokowski, B; Keren, G; Mark, Z; Rubinstein, E, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 40 (21.51) | 18.7374 |
| 1990's | 70 (37.63) | 18.2507 |
| 2000's | 63 (33.87) | 29.6817 |
| 2010's | 12 (6.45) | 24.3611 |
| 2020's | 1 (0.54) | 2.80 |
| Authors | Studies |
|---|---|
| Bhawsar, S | 1 |
| Joshi, S | 1 |
| Deshpande, P | 1 |
| Yeole, R | 1 |
| Bhagwat, S | 1 |
| Patel, M | 1 |
| Khasawneh, FA | 1 |
| Jou-Tindo, AJ | 1 |
| Rapp, RP | 1 |
| Zhang, YY | 2 |
| Huang, HH | 1 |
| Ren, ZY | 1 |
| Zheng, HG | 1 |
| Yu, YS | 2 |
| Lü, XJ | 1 |
| Xiao, ZK | 1 |
| Yang, HF | 1 |
| Xiu, QY | 1 |
| Chen, BY | 1 |
| Yue, HM | 1 |
| Hao, QL | 1 |
| Huang, JA | 1 |
| Ma, H | 1 |
| Xiao, W | 1 |
| Guo, DY | 1 |
| Si, B | 1 |
| Sun, SH | 1 |
| Zhang, W | 1 |
| Li, QH | 1 |
| Shen, HH | 1 |
| Duan, J | 1 |
| Li, HY | 2 |
| Yao, WZ | 1 |
| Gu, JM | 1 |
| Xia, QM | 1 |
| Ying, KJ | 1 |
| Liu, A | 1 |
| Yang, HP | 1 |
| Shi, MH | 1 |
| Sun, TY | 1 |
| Ding, GH | 1 |
| Wu, GM | 1 |
| Yamaguchi, K | 4 |
| Ohno, A | 1 |
| Ishii, Y | 2 |
| Tateda, K | 2 |
| Iwata, M | 3 |
| Kanda, M | 2 |
| Akizawa, K | 1 |
| Shimizu, C | 1 |
| Kon, S | 1 |
| Nakamura, K | 1 |
| Matsuda, K | 1 |
| Tominaga, M | 1 |
| Nakagawa, T | 1 |
| Sugita, A | 1 |
| Ito, T | 1 |
| Kato, J | 1 |
| Suwabe, A | 1 |
| Yamahata, K | 1 |
| Kawamura, C | 2 |
| Tashiro, H | 2 |
| Horiuchi, H | 2 |
| Katayama, Y | 1 |
| Kondou, S | 1 |
| Misawa, S | 1 |
| Murata, M | 1 |
| Kobayashi, Y | 1 |
| Okamoto, H | 2 |
| Yamazaki, K | 1 |
| Okada, M | 1 |
| Haruki, K | 1 |
| Kanno, H | 2 |
| Aihara, M | 1 |
| Maesaki, S | 3 |
| Hashikita, G | 1 |
| Miyajima, E | 1 |
| Sumitomo, M | 1 |
| Saito, T | 1 |
| Yamane, N | 2 |
| Kawashima, C | 1 |
| Akiyama, T | 1 |
| Ieiri, T | 1 |
| Yamamoto, Y | 1 |
| Okamoto, Y | 1 |
| Okabe, H | 1 |
| Moro, K | 1 |
| Shigeta, M | 1 |
| Yoshida, H | 1 |
| Yamashita, M | 1 |
| Hida, Y | 1 |
| Takubo, T | 1 |
| Kusakabe, T | 1 |
| Masaki, H | 1 |
| Heijyou, H | 1 |
| Nakaya, H | 1 |
| Kawahara, K | 1 |
| Sano, R | 1 |
| Matsuo, S | 1 |
| Kono, H | 2 |
| Yuzuki, Y | 1 |
| Ikeda, N | 1 |
| Idomuki, M | 1 |
| Soma, M | 1 |
| Yamamoto, G | 1 |
| Kinoshita, S | 1 |
| Kawano, S | 1 |
| Oka, M | 1 |
| Kusano, N | 2 |
| Kang, D | 1 |
| Ono, J | 2 |
| Yasujima, M | 2 |
| Miki, M | 1 |
| Hayashi, M | 1 |
| Okubo, S | 2 |
| Toyoshima, S | 2 |
| Kaku, M | 3 |
| Sekine, I | 1 |
| Shiotani, J | 1 |
| Tazawa, Y | 2 |
| Yoneyama, A | 1 |
| Kumasaka, K | 1 |
| Koike, K | 1 |
| Taniguchi, N | 1 |
| Ozaki, Y | 1 |
| Uchida, T | 1 |
| Murakami, M | 1 |
| Inuzuka, K | 1 |
| Gonda, H | 1 |
| Yamaguchi, I | 1 |
| fujimoto, Y | 1 |
| Iriyama, J | 1 |
| Asano, Y | 1 |
| Genma, H | 1 |
| Maekawa, M | 1 |
| Yoshimura, H | 1 |
| Nakatani, K | 1 |
| Baba, H | 1 |
| Ichiyama, S | 1 |
| Fujita, S | 1 |
| Kuwabara, M | 2 |
| Okazaki, T | 1 |
| Fujiwara, H | 1 |
| Ota, H | 1 |
| Nagai, A | 1 |
| Fujita, J | 1 |
| Negayama, K | 2 |
| Sugiura, T | 1 |
| Kamioka, M | 1 |
| Murase, M | 1 |
| Nakasone, I | 2 |
| Okayama, A | 1 |
| Aoki, Y | 1 |
| Kusaba, K | 1 |
| Nakashima, Y | 1 |
| Miyanohara, H | 1 |
| Hiramatsu, K | 1 |
| Saikawa, T | 1 |
| Yanagihara, K | 2 |
| Matsuda, J | 1 |
| Kohno, S | 3 |
| Mashiba, K | 1 |
| Zhang, J | 1 |
| Xie, X | 1 |
| Zhou, X | 1 |
| Chen, YQ | 1 |
| Yu, JC | 1 |
| Cao, GY | 1 |
| Wu, XJ | 1 |
| Shi, YG | 1 |
| Pyles, RB | 1 |
| Jezek, GE | 1 |
| Eaves-Pyles, TD | 1 |
| Drago, L | 2 |
| Nicola, L | 2 |
| Mattina, R | 1 |
| De Vecchi, E | 2 |
| Pea, F | 3 |
| Glass, SK | 1 |
| Pearl, DL | 1 |
| McEwen, SA | 1 |
| Finley, R | 1 |
| Wernicke, AG | 1 |
| Swistel, AJ | 1 |
| Parashar, B | 1 |
| Myskowski, PL | 1 |
| Płusa, T | 2 |
| Tiengrim, S | 1 |
| Phiboonbanakit, D | 1 |
| Thunyaharn, S | 1 |
| Tantisiriwat, W | 1 |
| Santiwatanakul, S | 1 |
| Susaengrat, W | 1 |
| Srisurat, N | 1 |
| Malithong, A | 1 |
| Srisangchan, P | 1 |
| Thamlikitkul, V | 1 |
| Torres, A | 1 |
| Liapikou, A | 1 |
| Leffel, EK | 1 |
| Bourdage, JS | 1 |
| Williamson, ED | 1 |
| Duchars, M | 1 |
| Fuerst, TR | 1 |
| Fusco, PC | 1 |
| Chen, Y | 1 |
| Yang, H | 1 |
| Lu, G | 1 |
| Wu, X | 1 |
| Huang, W | 1 |
| Wu, Y | 1 |
| Lv, X | 1 |
| Wu, G | 1 |
| Zhang, G | 1 |
| Li, Q | 1 |
| Sun, Y | 1 |
| Azoicai, D | 1 |
| Antoniu, SA | 1 |
| Roig, J | 1 |
| Martínez Benazet, J | 1 |
| Casal, J | 1 |
| Furlanut, M | 2 |
| Brollo, L | 1 |
| Lugatti, E | 1 |
| Di Qual, E | 1 |
| Dolcet, F | 1 |
| Talmassons, G | 1 |
| Iakovlev, SV | 1 |
| Iakovlev, VP | 2 |
| Gopal Rao, G | 1 |
| Mahankali Rao, CS | 1 |
| Starke, I | 1 |
| Matsuzaki, K | 2 |
| Watabe, E | 1 |
| Yoshimori, K | 1 |
| Shikano, M | 1 |
| Sato, Y | 3 |
| Hasegawa, M | 2 |
| Kobayashi, I | 2 |
| Odagiri, S | 3 |
| Watanuki, Y | 1 |
| Takahashi, H | 1 |
| Shimada, J | 1 |
| Karlowsky, JA | 3 |
| Thornsberry, C | 4 |
| Critchley, IA | 1 |
| Jones, ME | 3 |
| Evangelista, AT | 1 |
| Noel, GJ | 1 |
| Sahm, DF | 3 |
| Burgmann, H | 1 |
| Mayer, B | 1 |
| Lukas, A | 1 |
| Kumbein, F | 1 |
| Oberbauer, R | 1 |
| Gonzales, R | 1 |
| Sowinski, KM | 1 |
| Lucksiri, A | 1 |
| Kays, MB | 1 |
| Scott, MK | 1 |
| Mueller, BA | 1 |
| Hamburger, RJ | 1 |
| Blosser-Middleton, RS | 2 |
| Hua, CZ | 1 |
| Shang, SQ | 1 |
| Sun, XF | 1 |
| Li, JP | 1 |
| Chen, ZM | 1 |
| Yu, XL | 1 |
| Yamaguchi, H | 1 |
| Uchino, K | 1 |
| Yokoyama, H | 1 |
| Matsumoto, T | 1 |
| Alvarez-Lerma, F | 1 |
| Palomar, M | 1 |
| Olaechea, P | 1 |
| León, C | 1 |
| Sánchez, M | 1 |
| Bermejo, B | 1 |
| Wenzler, S | 1 |
| Schmidt-Eisenlohr, E | 1 |
| Daschner, F | 1 |
| Wang, H | 1 |
| Liu, Y | 1 |
| Hu, BJ | 1 |
| Sun, ZY | 1 |
| Chen, MJ | 1 |
| Mendes, C | 1 |
| Kiffer, CR | 1 |
| Barth, A | 1 |
| Rossi, F | 1 |
| Andrade, S | 1 |
| Sader, HS | 2 |
| Blasi, F | 1 |
| Fish, DN | 1 |
| Brown, SD | 1 |
| Farrell, DJ | 1 |
| Morrissey, I | 1 |
| Hoepelman, I | 1 |
| Zubkov, MN | 1 |
| Sinopal'nikov, AI | 1 |
| Romanovskiĭ, AG | 1 |
| Hermsen, ED | 1 |
| Hovde, LB | 1 |
| Konstantinides, GN | 1 |
| Rotschafer, JC | 1 |
| Fuller, JD | 1 |
| Low, DE | 1 |
| Jones, RN | 3 |
| Fritsche, TR | 1 |
| Coban, S | 1 |
| Ceydilek, B | 1 |
| Ekiz, F | 1 |
| Erden, E | 1 |
| Soykan, I | 1 |
| Brückner, O | 1 |
| Trautmann, M | 1 |
| Chuard, C | 2 |
| Regamey, C | 3 |
| Makaryus, AN | 1 |
| Byrns, K | 1 |
| Makaryus, MN | 1 |
| Natarajan, U | 1 |
| Singer, C | 1 |
| Goldner, B | 1 |
| Sollet, JP | 1 |
| Cantón, R | 1 |
| Lode, H | 2 |
| Graninger, W | 1 |
| Milkovich, G | 1 |
| Qin, L | 1 |
| Watanabe, H | 1 |
| Asoh, N | 1 |
| Watanabe, K | 3 |
| Oishi, K | 1 |
| Mizota, T | 1 |
| Nagatake, T | 1 |
| Khashab, MM | 1 |
| Xiang, J | 1 |
| Kahn, JB | 1 |
| Sun, HK | 1 |
| Du, X | 1 |
| DeRyke, CA | 1 |
| Doern, GV | 1 |
| Nicolau, DP | 1 |
| Shin, JH | 1 |
| Jung, HJ | 1 |
| Kim, HR | 1 |
| Jeong, J | 1 |
| Jeong, SH | 1 |
| Kim, S | 1 |
| Lee, EY | 1 |
| Lee, JN | 1 |
| Chang, CL | 1 |
| Ivanov, DV | 1 |
| Budanov, SV | 2 |
| Omika, K | 1 |
| Gismondo, MR | 1 |
| Tan, C | 1 |
| Zhu, WY | 1 |
| Min, ZS | 1 |
| Gibert, AE | 1 |
| Porta, FS | 1 |
| Kobayashi, H | 2 |
| Takamura, K | 1 |
| Kono, K | 1 |
| Onodera, S | 1 |
| Sasaki, N | 1 |
| Nagahama, F | 1 |
| Kawakami, Y | 1 |
| Honma, Y | 1 |
| Matsuzaki, M | 1 |
| Tanimura, K | 1 |
| Watanabe, A | 2 |
| Oizumi, K | 2 |
| Motomiya, M | 1 |
| Nukiwa, T | 1 |
| Davis, R | 1 |
| Bryson, HM | 1 |
| Zhuo, HT | 2 |
| Lu, JZ | 1 |
| Xia, XR | 1 |
| Ling, SS | 1 |
| Yano, T | 1 |
| Tanaka, F | 1 |
| Ouchi, K | 1 |
| Kawahara, M | 1 |
| Fujino, K | 1 |
| Shima, R | 1 |
| Rikimaru, T | 1 |
| Ichikawa, Y | 1 |
| Li, Z | 1 |
| Chen, G | 1 |
| Hoban, DJ | 1 |
| Koizumi, F | 1 |
| Ohnishi, A | 1 |
| Takemura, H | 1 |
| Kagami, T | 1 |
| Tanaka, T | 1 |
| Körner, RJ | 1 |
| Reeves, DS | 1 |
| MacGowan, AP | 1 |
| Malmborg, AS | 1 |
| Ahlén, S | 1 |
| Hou, SR | 1 |
| Frank-Piskorska, A | 1 |
| Józefczak, E | 1 |
| Kałczak, M | 1 |
| Spivey, IM | 1 |
| Fukuhara, H | 1 |
| Irabu, Y | 1 |
| Shigeno, Y | 1 |
| Saito, A | 3 |
| Nakamura, H | 1 |
| Horimoto, S | 1 |
| Shimozi, T | 1 |
| Miyagi, M | 1 |
| Inadame, J | 1 |
| Kawahara, S | 2 |
| Watanabe, Y | 1 |
| Matsuka, Y | 1 |
| Sato, T | 1 |
| Takahashi, K | 1 |
| Kawai, T | 1 |
| Nakamori, Y | 2 |
| Miyashita, Y | 1 |
| Nakatani, I | 1 |
| Nakata, K | 2 |
| Sato, A | 1 |
| Ogawa, H | 1 |
| Ono, T | 1 |
| Yasuda, K | 1 |
| Nagayama, M | 1 |
| Shirai, T | 1 |
| Shirai, M | 1 |
| Ida, M | 1 |
| Suda, T | 1 |
| Sawae, Y | 2 |
| Ninomiya, K | 1 |
| Takaki, K | 1 |
| Shimono, N | 1 |
| Misumi, H | 1 |
| Okada, K | 1 |
| Shishido, H | 1 |
| Furukawa, K | 1 |
| Nagai, H | 1 |
| Kawakami, K | 1 |
| Sufarlan, AW | 1 |
| Zainudin, BM | 1 |
| Pit, S | 1 |
| Ishak, I | 1 |
| Tomasic-Cvitanovic, S | 1 |
| Kotaraki, Z | 1 |
| Yoshida, M | 1 |
| Ishibashi, T | 1 |
| Yamada, H | 1 |
| Kido, M | 1 |
| Hirose, T | 1 |
| Maeda, F | 1 |
| Matsuzaki, Y | 1 |
| Goldstein, FW | 1 |
| Acar, JF | 1 |
| Blatun, LA | 1 |
| Svetukhin, AM | 1 |
| Puchkova, LS | 1 |
| Izotova, GN | 1 |
| Navashin, SM | 1 |
| Navashin, PS | 1 |
| Smirnova, LB | 2 |
| Hoogkamp-Korstanje, JA | 1 |
| Andrews, JM | 2 |
| Honeybourne, D | 1 |
| Jevons, G | 1 |
| Brenwald, NP | 1 |
| Cunningham, B | 1 |
| Wise, R | 2 |
| Jakubicz, P | 1 |
| Leszczyńska, K | 1 |
| Preston, SL | 1 |
| Drusano, GL | 1 |
| Berman, AL | 1 |
| Fowler, CL | 1 |
| Chow, AT | 1 |
| Dornseif, B | 1 |
| Reichl, V | 1 |
| Natarajan, J | 1 |
| Corrado, M | 1 |
| Ogilvie, P | 1 |
| Kahn, J | 1 |
| Mauriz, Y | 1 |
| Yoshizumi, S | 1 |
| Domon, H | 1 |
| Miyazaki, S | 3 |
| Langtry, HD | 1 |
| Lamb, HM | 1 |
| Vila, J | 1 |
| Ruiz, J | 1 |
| Sanchez, F | 1 |
| Navarro, F | 1 |
| Mirelis, B | 1 |
| de Anta, MT | 1 |
| Prats, G | 1 |
| Yasuda, H | 1 |
| Yoshida, A | 1 |
| Masuda, Y | 1 |
| Fukayama, M | 1 |
| Kita, Y | 1 |
| Inamatsu, T | 1 |
| Redondo Sánchez, J | 1 |
| García-Rodríguez, JA | 1 |
| Muñoz Bellido, JL | 1 |
| Alonso Manzanares, MA | 1 |
| Gutiérrez Zufiaurre, MN | 1 |
| Fujita, A | 1 |
| Miya, T | 1 |
| Tanaka, R | 1 |
| Hirayama, S | 1 |
| Isaka, H | 1 |
| Ono, Y | 1 |
| Koshiishi, Y | 1 |
| Goya, T | 1 |
| Hooper, DC | 2 |
| Tomono, K | 1 |
| Sawai, T | 1 |
| Kuroki, M | 1 |
| Kaneko, Y | 1 |
| Ohno, H | 1 |
| Higashiyama, Y | 1 |
| Miyazaki, Y | 2 |
| Hirakata, Y | 1 |
| Kadota, J | 1 |
| Tashiro, T | 1 |
| Kashitani, F | 1 |
| Tsujio, Y | 1 |
| Okada, J | 1 |
| Watanabe, N | 1 |
| Uehara, N | 1 |
| Igari, J | 1 |
| Oguri, T | 1 |
| Kaimori, M | 1 |
| Iinuma, Y | 1 |
| Nisawataira, T | 1 |
| Ueno, K | 1 |
| Ishigo, S | 1 |
| Itoh, C | 1 |
| Yoshida, T | 1 |
| Yamanaka, K | 1 |
| Katoh, J | 1 |
| Kudoh, M | 1 |
| Matsushima, T | 1 |
| Niki, Y | 1 |
| Miyashita, N | 1 |
| Funato, T | 1 |
| Sato, N | 1 |
| Saito, Y | 1 |
| Ishii, K | 1 |
| Hongo, T | 1 |
| Kamihira, S | 1 |
| Takii, M | 2 |
| Ishii, M | 1 |
| Nakagawa, K | 1 |
| Takada, T | 1 |
| Murakami, N | 1 |
| Taira, M | 1 |
| Tamaki, I | 1 |
| Matsudou, Y | 1 |
| Kamei, T | 1 |
| Toriumi, Y | 1 |
| Tomioka, H | 1 |
| Shah, PM | 2 |
| Liam, CK | 1 |
| Aziah, AM | 1 |
| Lim, KH | 1 |
| Wong, CM | 1 |
| Inoue, M | 1 |
| Kuga, A | 1 |
| Kaieda, S | 1 |
| Hosaka, M | 1 |
| Kitasato, H | 1 |
| Okamoto, R | 1 |
| Eda, T | 1 |
| Hoshino, K | 1 |
| Seto, I | 1 |
| Schentag, JJ | 1 |
| Gilliland, KK | 1 |
| Paladino, JA | 1 |
| Martin, SJ | 1 |
| Jung, R | 1 |
| Garvin, CG | 1 |
| Dan, M | 1 |
| Poch, F | 1 |
| Asherov, J | 1 |
| Postnikov, SS | 1 |
| Lopez, H | 1 |
| Vilches, V | 1 |
| Scarano, S | 1 |
| Stepanik, D | 1 |
| Smayevsky, J | 1 |
| Lemme, L | 1 |
| Cardeñosa, O | 1 |
| Ambler, J | 1 |
| Sucari, A | 1 |
| Vasil'ev, AN | 1 |
| Rossi, C | 1 |
| Sternon, J | 1 |
| Hutchinson, J | 1 |
| De Simone, C | 1 |
| Trinchieri, V | 1 |
| Tzantzoglou, S | 1 |
| Famularo, G | 1 |
| Moretti, S | 1 |
| Delia, S | 1 |
| Marcos Sánchez, F | 1 |
| Aparicio Martínez, JC | 1 |
| Celdrán Gil, J | 1 |
| Durán Pérez-Navarro, A | 1 |
| Aoki, N | 1 |
| Usuda, Y | 1 |
| Koda, Y | 1 |
| Takasawa, T | 1 |
| Wakabayashi, N | 1 |
| Hayashi, S | 1 |
| Nitta, I | 1 |
| Honma, C | 1 |
| Tsuboi, E | 1 |
| Narui, K | 1 |
| Nakatani, T | 1 |
| Sugi, H | 1 |
| Tanaka, K | 2 |
| Iwamoto, M | 1 |
| Koga, H | 1 |
| Hara, K | 1 |
| Sugawara, K | 1 |
| Kusano, S | 1 |
| Sakito, O | 1 |
| Romano, L | 1 |
| Girosi, D | 1 |
| Spallone, E | 1 |
| Parisi, F | 1 |
| Minicucci, L | 1 |
| Romano, C | 1 |
| Takagi, K | 1 |
| Hasegawa, T | 1 |
| Yamaki, K | 1 |
| Suzuki, K | 2 |
| Nabeshima, T | 1 |
| Cherubin, CE | 1 |
| Eng, RH | 1 |
| Smith, SM | 1 |
| Tan, EN | 1 |
| Reller, LB | 1 |
| Rosati, LA | 1 |
| Erwin, ME | 1 |
| Sanchez, ML | 1 |
| Eron, LJ | 1 |
| Gentry, LO | 1 |
| Hardy, DJ | 3 |
| Ozaki, M | 1 |
| Matsuda, M | 1 |
| Tomii, Y | 1 |
| Kimura, K | 1 |
| Segawa, J | 1 |
| Kitano, M | 1 |
| Kise, M | 1 |
| Shibata, K | 1 |
| Otsuki, M | 1 |
| Nishino, T | 2 |
| Peugeot, RL | 1 |
| Lipsky, BA | 2 |
| Hooton, TM | 1 |
| Pecoraro, RE | 1 |
| Feist, H | 1 |
| Ritrovato, CA | 1 |
| Deeter, RG | 1 |
| Swanson, RN | 1 |
| Chu, DT | 1 |
| Shipkowitz, NL | 1 |
| Clement, JJ | 1 |
| Kashiwagi, S | 1 |
| Kumagai, Y | 1 |
| Ishimaru, T | 1 |
| Shigeoka, H | 1 |
| Kuwabara, K | 1 |
| Takita, A | 1 |
| Muranishi, T | 1 |
| Nagafuchi, S | 1 |
| Biglino, A | 1 |
| Forno, B | 1 |
| Pollono, AM | 1 |
| Busso, M | 1 |
| Arpinelli, F | 1 |
| Benedetti, M | 1 |
| Pugliese, A | 1 |
| Wiley, E | 1 |
| Olschewski, P | 1 |
| Sievers, H | 1 |
| Wintermantel, M | 1 |
| Baetz, R | 1 |
| Lebahn, K | 1 |
| Reinke, M | 1 |
| Wagner, J | 1 |
| Borner, K | 1 |
| Kanellakopoulou, K | 1 |
| Giamarellou, H | 1 |
| Ball, P | 1 |
| Tack, KJ | 1 |
| Kuo, CC | 1 |
| Wang, SP | 1 |
| Grayston, JT | 1 |
| Steinbach-Lebbin, C | 1 |
| Perea, EJ | 1 |
| Khajotia, R | 1 |
| Drlicek, M | 1 |
| Vetter, N | 1 |
| Krcméry, V | 1 |
| Cernák, P | 1 |
| Cepcek, P | 1 |
| Stapel, A | 1 |
| Freymann, H | 1 |
| Ruge, W | 1 |
| Pace, JL | 1 |
| Gatt, P | 1 |
| Waldvogel, FA | 1 |
| Stocks, JM | 1 |
| Wallace, RJ | 1 |
| Griffith, DE | 1 |
| Garcia, JG | 1 |
| Kohler, RB | 1 |
| Cristiano, P | 2 |
| Iovene, MR | 1 |
| Morelli, G | 2 |
| Mandia, L | 1 |
| Paradisi, F | 2 |
| Altucci, P | 2 |
| Suzuki, H | 1 |
| Shimizu, S | 1 |
| Otsuka, H | 1 |
| Takagi, H | 1 |
| Akisawa, T | 1 |
| Narushima, M | 1 |
| Tonotsuka, H | 1 |
| Kaneshige, H | 1 |
| Nakagami, K | 1 |
| Neu, HC | 2 |
| Kurz, CC | 1 |
| Marget, W | 1 |
| Harms, K | 1 |
| Bertele, RM | 1 |
| Rubin, AR | 1 |
| Musiał, J | 1 |
| Sładek, K | 1 |
| Kotlinowska, T | 1 |
| Szczeklik, A | 1 |
| Nakatomi, M | 1 |
| Suermondt, G | 1 |
| Denamur, E | 1 |
| Laurans, G | 1 |
| Orfila, J | 1 |
| Muraki, N | 1 |
| Chen, RM | 1 |
| Kakusaka, I | 1 |
| Kuriyama, T | 1 |
| Kikuchi, N | 1 |
| Yamagishi, F | 1 |
| Yamamoto, T | 1 |
| Watanabe, S | 1 |
| Moorhouse, EC | 1 |
| Clarke, PC | 1 |
| Obana, Y | 1 |
| Konno, M | 1 |
| Ohno, I | 1 |
| Ida, S | 1 |
| Bertrand, A | 1 |
| Janbon, F | 1 |
| Despaux, E | 1 |
| Jonquet, O | 1 |
| Reynes, J | 1 |
| Maesen, FP | 3 |
| Davies, BI | 3 |
| Geraedts, WH | 1 |
| Baur, C | 2 |
| Grassi, C | 1 |
| Gialdroni Grassi, G | 1 |
| Mangiarotti, P | 1 |
| Katsu, M | 1 |
| Soejima, R | 1 |
| Hasçelik, G | 1 |
| Sumajow, CA | 1 |
| Devogelaere, R | 1 |
| Maes, P | 1 |
| Bariffi, F | 1 |
| Giacomelli, P | 1 |
| Sanduzzi, A | 1 |
| Perna, F | 1 |
| De Masi, AL | 1 |
| Meyer, H | 1 |
| Hänninen, P | 1 |
| Harazim, H | 1 |
| Wimmer, J | 1 |
| Mittermayer, HP | 1 |
| Ludwig, G | 1 |
| Pauthner, H | 1 |
| Blomer, R | 1 |
| Bruch, K | 1 |
| Zahlten, RN | 1 |
| Rubinstein, E | 1 |
| Mark, Z | 1 |
| Keren, G | 1 |
| Alkan, M | 1 |
| Berger, S | 1 |
| Bogokowski, B | 1 |
| Knothe, H | 1 |
| Lam, WK | 1 |
| Chau, PY | 1 |
| So, SY | 1 |
| Leung, YK | 1 |
| Chan, JC | 1 |
| Sham, MK | 1 |
| Grassi, GG | 1 |
| Leonessa, V | 1 |
| Briante, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Non-Inferiority Study for Shortening Tuberculosis Treatment With Sitafloxacin-Containing Regimens[NCT05454345] | Phase 3 | 620 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | ||
| [NCT02729116] | Phase 2/Phase 3 | 30 participants (Anticipated) | Interventional | 2016-07-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
32 reviews available for ofloxacin and Infections, Respiratory
| Article | Year |
|---|---|
[PK/PD profile and post-marketing surveillance of levofloxacin].
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Cohort Studies; Drug Resistance, Multiple, Bacteri | 2009 |
Levofloxacin-induced radiation recall dermatitis: a case report and a review of the literature.
Topics: Anti-Bacterial Agents; Breast Neoplasms; Carcinoma, Lobular; Female; Humans; Levofloxacin; Middle Ag | 2010 |
Levofloxacin for the treatment of respiratory tract infections.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Cross Infection; Humans; Levofloxacin; Ofloxac | 2012 |
MP-376 (Aeroquin) for chronic Pseudomonas aeruginosa infections.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Chronic Disease; Clinical Trials as Topic; Drug D | 2013 |
[Levofloxacin in the treatment of respiratory infections].
Topics: Acute Disease; Anti-Infective Agents; Bronchitis, Chronic; Clinical Trials as Topic; Drug Resistance | 2002 |
Levofloxacin PK/PD: from sequential therapy model to high dosage for critical patients.
Topics: Administration, Oral; Anti-Infective Agents; Area Under Curve; Biological Availability; Case-Control | 2004 |
Role of levofloxacin in the treatment of lower respiratory tract infections (LRTIs).
Topics: Administration, Oral; Anti-Infective Agents; Bronchitis; Chronic Disease; Community-Acquired Infecti | 2004 |
Levofloxacin: update and perspectives on one of the original 'respiratory quinolones'.
Topics: Animals; Drug Resistance, Microbial; Humans; Levofloxacin; Ofloxacin; Quinolones; Respiratory Tract | 2003 |
[New fluoroquinolones: levofloxacin, moxifloxacin and gatifloxacin].
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gr | 2004 |
[Efficacy and safety of levofloxacin in low respiratory tract infection].
Topics: Anti-Bacterial Agents; Central Nervous System Diseases; Clinical Trials as Topic; Dermatitis, Atopic | 2004 |
[Levofloxacin: role and place in the treatment of infections of the lower respiratory tracts].
Topics: Anti-Bacterial Agents; Bacterial Infections; Central Nervous System; Drug Resistance, Bacterial; Hum | 2004 |
A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Female; F | 2005 |
Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
Topics: Anti-Bacterial Agents; Bronchitis, Chronic; Community-Acquired Infections; Fluoroquinolones; Humans; | 2006 |
Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections.
Topics: Anti-Bacterial Agents; Clinical Trials as Topic; Humans; Levofloxacin; Ofloxacin; Respiratory Tract | 2006 |
[Levofloxacin and other antibacterial drugs].
Topics: Anti-Bacterial Agents; Bacterial Infections; Dermatitis; Dosage Forms; Humans; Levofloxacin; Ofloxac | 2006 |
Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy.
Topics: Administration, Oral; Aging; Bacteria; Bacterial Infections; Biological Availability; Drug Interacti | 1994 |
[Ten-year experience with the use of ofloxacin (Tarivid*). New treatment regimens].
Topics: Anti-Infective Agents; Drug Administration Schedule; Humans; Ofloxacin; Respiratory Tract Infections | 1996 |
Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.
Topics: Animals; Anti-Infective Agents; Humans; Levofloxacin; Ofloxacin; Respiratory Tract Infections; Skin | 1998 |
New fluoroquinolone antibiotics.
Topics: Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Pipe | 1999 |
[Levofloxacin for prevalent infections in primary care medicine].
Topics: Anti-Infective Agents; Bacterial Infections; Community-Acquired Infections; Humans; Levofloxacin; Of | 1999 |
[The present and future of levofloxacin in the treatment of respiratory infections].
Topics: Anti-Infective Agents; Clinical Trials as Topic; Humans; Levofloxacin; Models, Molecular; Ofloxacin; | 1999 |
New uses for new and old quinolones and the challenge of resistance.
Topics: Anti-Infective Agents; Bacterial Infections; Drug Resistance, Microbial; Fluoroquinolones; Humans; M | 2000 |
The fluoroquinolones after ciprofloxacin and ofloxacin.
Topics: Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Humans; Naphthyridines; Ofloxacin; Pi | 2000 |
The use of levofloxacin in the treatment of respiratory tract infection.
Topics: Anti-Infective Agents; Bronchitis; Chronic Disease; Community-Acquired Infections; Haemophilus Infec | 2000 |
What have we learned from pharmacokinetic and pharmacodynamic theories?
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Community-Acquired Infections; Drug Resistanc | 2001 |
A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
Topics: Animals; Anti-Infective Agents; Drug Resistance, Microbial; Drug-Related Side Effects and Adverse Re | 2001 |
[The first 'respiration' fluoroquinolone--levofloxacin (Tavanic) in therapy of bacterial infections. Pharmacodynamics principles in optimization of administration regimens].
Topics: Acute Disease; Animals; Anti-Infective Agents; Bronchitis; Chronic Disease; Community-Acquired Infec | 2001 |
[Third and fourth generation fluoroquinolones].
Topics: Administration, Oral; Anti-Infective Agents; Aza Compounds; Belgium; Biological Availability; Drug M | 2001 |
Respiratory tract penetration of quinolone antimicrobials: a case in study.
Topics: Anti-Infective Agents; Bronchi; Humans; Lung; Ofloxacin; Respiratory Tract Infections; Saliva; Sputu | 1991 |
Ofloxacin concentrations in tissues involved in respiratory tract infections.
Topics: Bronchi; Humans; Lung; Ofloxacin; Respiratory Tract Infections; Sputum | 1990 |
[Refractory respiratory tract infections. 6. New problems in refractory respiratory tract infections. c. Chemotherapy of methicillin-resistant Staphylococci infection].
Topics: Anti-Bacterial Agents; Cefmetazole; Cephamycins; Drug Therapy, Combination; Fosfomycin; Humans; Meth | 1987 |
[Refractory respiratory tract infections. 7. Trends in the development of new chemotherapeutic agents for respiratory tract infections. b. Synthetic antibacterial agents].
Topics: 4-Quinolones; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Ciprofloxacin; Drug Resistance | 1987 |
52 trials available for ofloxacin and Infections, Respiratory
| Article | Year |
|---|---|
Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China.
Topics: Administration, Oral; Adolescent; Aged; Anti-Bacterial Agents; China; Dizziness; Drug Administration | 2009 |
Permeability and concentration of levofloxacin in epithelial lining fluid in patients with lower respiratory tract infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Area Under Curve; Bronchoalveolar Lavage Fluid; Female; Humans; | 2010 |
Prulifloxacin versus levofloxacin in the treatment of respiratory and urinary tract infections: a multicentre, double-blind, randomized controlled clinical trial.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Dioxolanes; Disk Diffusion Antimicrobial Tests; Doub | 2012 |
Clostridium difficile-associated diarrhoea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with beta-lactam-based therapy.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Chi-Square Distribution; Clostridioides difficile; Commun | 2003 |
Short report: antimicrobial susceptibility and genetic characteristics of Haemophilus influenzae isolated from patients with respiratory tract infections between 1987 and 2000, including beta-lactamase-negative ampicillin-resistant strains.
Topics: Ampicillin; Anti-Bacterial Agents; beta-Lactam Resistance; Ceftriaxone; Female; Haemophilus Infectio | 2007 |
[Comparison of DL-8280 and amoxicillin in the treatment of respiratory tract infections].
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bronchiectasis; Bronchitis; Clinical Trials as Topi | 1984 |
Clinical studies of oral quinolone once daily in the treatment of lower respiratory tract infections.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacteria; Drug Administration Schedule; Female | 1993 |
Application of NONMEM method for evaluation of relative biological availability of ofloxacin.
Topics: Adult; Biological Availability; Female; Humans; Male; Middle Aged; Nonlinear Dynamics; Ofloxacin; Re | 1994 |
[Clinical study of Chinese ofloxacin].
Topics: Adolescent; Adult; Aged; Female; Gonorrhea; Humans; Male; Middle Aged; Ofloxacin; Respiratory Tract | 1993 |
[Clinical studies of ofloxacin 300 mg once a day administration in chronic respiratory tract infections].
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Blood Urea Nitrogen; Creatinine; Drug Administ | 1993 |
Inhibitory effect of ofloxacin on acute exacerbations of chronic respiratory tract infections in comparison with erythromycin.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Chronic Disease; Cross | 1995 |
Clinical evaluation of levofloxacin 200 mg 3 times daily in the treatment of bacterial lower respiratory tract infections.
Topics: Adult; Aged; Anti-Infective Agents; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Resp | 1995 |
Levofloxacin: penetration into sputum and once-daily treatment of respiratory tract infections.
Topics: Adult; Aged; Anti-Infective Agents; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Resp | 1995 |
Clinical efficacy of levofloxacin in elderly patients with respiratory tract infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Female; Humans; Levofloxacin; Male; Middle Ag | 1995 |
A comparative study of ofloxacin twice and three times daily in the treatment of respiratory tract infections.
Topics: Anti-Infective Agents; Female; Humans; Male; Middle Aged; Ofloxacin; Respiratory Tract Infections | 1995 |
Oral levofloxacin 600 mg and 300 mg daily doses in difficult-to-treat respiratory infections.
Topics: Adult; Aged; Anti-Infective Agents; Double-Blind Method; Female; Humans; Levofloxacin; Male; Middle | 1995 |
Causative organisms in acute exacerbation of chronic airways disease and response to ofloxacin therapy.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Chronic Disease; Female; Humans; Male; Middle Aged; | 1995 |
Efficacy of ofloxacin in lower respiratory tract infections bacteriologically diagnosed by fibreoptic-bronchoscopy aspirate culture.
Topics: Anti-Infective Agents; Bronchoscopy; Female; Fiber Optic Technology; Humans; Lung; Male; Ofloxacin; | 1995 |
Clinical efficacy of ofloxacin in acute exacerbations of chronic respiratory disease.
Topics: Anti-Infective Agents; Chronic Disease; Humans; Ofloxacin; Respiratory Tract Infections | 1995 |
Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials.
Topics: Adult; Anti-Infective Agents; Area Under Curve; Bacterial Infections; Bayes Theorem; Dose-Response R | 1998 |
Crossover assessment of serum bactericidal activity of grepafloxacin, ofloxacin and clarithromycin against respiratory pathogens after oral administration to healthy volunteers.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Blood Bactericidal Activi | 2001 |
AIDS patients with bacterial lower respiratory tract infections: treatment with ofloxacin versus sulbactam-ampicillin.
Topics: Adult; AIDS-Related Opportunistic Infections; Ampicillin; Bacterial Infections; Drug Therapy, Combin | 1992 |
[The use of ofloxacin in cystic fibrosis patients].
Topics: Adolescent; Adult; Analysis of Variance; Chronic Disease; Cystic Fibrosis; Drug Tolerance; Female; H | 1992 |
Oral ofloxacin for infections caused by bacteria resistant to oral antimicrobial agents.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Diabetes Complications; Drug Resistance, Mi | 1992 |
Treatment of lower respiratory infections in outpatients with ofloxacin compared with erythromycin.
Topics: Adult; Aged; Bronchitis; Chlamydia Infections; Erythromycin; Female; Humans; Legionnaires' Disease; | 1991 |
Sequential therapy with i.v. and oral ofloxacin in lower respiratory tract infections: a comparative study.
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Bacte | 1991 |
Once daily versus every two week multidose ofloxacin in patients with acute exacerbations of chronic respiratory disease.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Bacterial Infections; Bronchiectasis; Bronchitis; Chr | 1991 |
[Clinical studies on the utility of ofloxacin for lower respiratory infections].
Topics: Adult; Aged; Bacteria; Drug Administration Schedule; Drug Resistance, Microbial; Female; Humans; Mal | 1991 |
Prospective randomized clinical trials of new quinolones versus beta-lactam antibiotics in lower respiratory tract infections.
Topics: Cilastatin; Cilastatin, Imipenem Drug Combination; Ciprofloxacin; Clavulanic Acids; Drug Combination | 1990 |
Clinical experience with parenteral and oral ofloxacin in severe infections.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Bacteria, Aerobic; Bacterial Infec | 1990 |
Overview of experience with ofloxacin in respiratory tract infection.
Topics: Bronchitis; Chronic Disease; Humans; Ofloxacin; Pneumonia; Remission Induction; Respiratory Tract In | 1990 |
Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections.
Topics: Aged; Bronchitis; Chlamydia; Chlamydia Infections; Clinical Trials as Topic; Drug Resistance, Microb | 1990 |
Severe infections treated with intravenous ofloxacin: a prospective clinical multicentre Swiss study.
Topics: Adolescent; Adult; Aged; Female; Gastrointestinal Diseases; Humans; Injections, Intravenous; Male; M | 1990 |
A comparative study of ofloxacin and amoxycillin/clavulanate in hospitalized patients with lower respiratory tract infections.
Topics: Administration, Oral; Adolescent; Adult; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; | 1990 |
[Significance of ofloxacin for the treatment of infection-exacerbated chronic obstructive lung disease].
Topics: Aged; Confusion; Humans; Lung Diseases, Obstructive; Middle Aged; Ofloxacin; Respiratory Tract Infec | 1990 |
Ofloxacin in community-acquired lower respiratory infections. A comparison with amoxicillin or erythromycin.
Topics: Adult; Amoxicillin; Bronchitis; Erythromycin; Female; Humans; Lung Diseases, Obstructive; Male; Midd | 1989 |
[Effect and tolerance of ofloxacin in bronchopulmonary infections in comparison with amoxicillin].
Topics: Aged; Amoxicillin; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Ofloxacin; Pneum | 1989 |
[A cross-over study on the effectiveness of ofloxacin and ciprofloxacin administered orally].
Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Clinical Trials as To | 1986 |
[Effectiveness of ofloxacin in the treatment of bacterial infections of the respiratory tract].
Topics: Adult; Aged; Bacterial Infections; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Oflo | 1988 |
The use of quinolones in respiratory tract infections.
Topics: Anti-Infective Agents; Bronchitis; Chronic Disease; Clinical Trials as Topic; Humans; Microbial Sens | 1987 |
Clinical efficacy of ofloxacin in lower respiratory tract infections. A multicentre study.
Topics: Aged; Anti-Infective Agents; Clinical Trials as Topic; Humans; Microbial Sensitivity Tests; Middle A | 1987 |
Ofloxacin in respiratory tract infection. A review of the results of clinical trials in Japan.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Clinical Trials as Topic; Humans; Japan; Middle Aged | 1987 |
Clinical, microbiological and pharmacokinetic studies on ofloxacin in acute purulent exacerbations of chronic respiratory disease.
Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Chronic Disease; Drug Therapy, Combination; Fe | 1986 |
Ofloxacin in lower respiratory tract infections--a comparison with amoxicillin.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Female; Humans; Male; Middle Aged; Ofloxacin; Oxazi | 1986 |
A comparative study of ofloxacin versus cefazolin in lower respiratory tract infections.
Topics: Adult; Aged; Anti-Infective Agents; Cefazolin; Female; Humans; Male; Middle Aged; Ofloxacin; Oxazine | 1987 |
An open randomised comparison of ofloxacin and doxycycline in lower respiratory tract infections.
Topics: Anti-Infective Agents; Bronchitis; Chronic Disease; Doxycycline; Humans; Microbial Sensitivity Tests | 1987 |
Clinical experience with ofloxacin in upper and lower urinary tract infections. A comparison with co-trimoxazole and nitrofurantoin.
Topics: Anti-Infective Agents; Drug Combinations; Female; Humans; Male; Microbial Sensitivity Tests; Nitrofu | 1987 |
[Summarized results of clinical phase II and III studies with ofloxacin (HOE 280) in Europe].
Topics: Anti-Infective Agents; Bacterial Infections; Clinical Trials as Topic; Drug Evaluation; Drug Resista | 1986 |
[Respiratory tract infections--clinical results with ofloxacin].
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Clinical Trials as | 1986 |
A double-blind randomized study comparing ofloxacin and amoxicillin in treating infective episodes in bronchiectasis.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bronchiectasis; Clinical Trials as Topic; Double-Bl | 1986 |
A multicenter study on clinical efficacy of ofloxacin in respiratory and urinary tract infections.
Topics: Adult; Aged; Anti-Infective Agents; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Ofl | 1986 |
Clinical experience with ofloxacin (DL 8280) in the therapy of various infections: preliminary report.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Cholangitis; Clinical Trials a | 1986 |
102 other studies available for ofloxacin and Infections, Respiratory
| Article | Year |
|---|---|
WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Fluoroquinolones; Humans; Microbial Sensiti | 2022 |
A 30-year-old woman with recurrent lower respiratory tract infections.
Topics: Adult; Anti-Bacterial Agents; Comorbidity; Diverticulum; Female; Humans; Ofloxacin; Radiography, Tho | 2013 |
Clinical and economic outcomes in respiratory tract infections: The impact of bacterial resistance.
Topics: Amoxicillin; Anti-Bacterial Agents; Azithromycin; Community-Acquired Infections; Doxycycline; Drug R | 2002 |
[In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,919 clinical isolates obtained from 72 centers in 2007].
Topics: Anti-Bacterial Agents; Bacteria; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; G | 2009 |
Toll-like receptor 3 agonist protection against experimental Francisella tularensis respiratory tract infection.
Topics: Animals; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Cells, Cultured; Colony Count, Microbi | 2010 |
In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Dioxolanes; DNA Gyrase; DNA Mutational Ana | 2010 |
A province-level risk factor analysis of fluoroquinolone consumption patterns in Canada (2000-06).
Topics: Anti-Bacterial Agents; Canada; Ciprofloxacin; Drug Utilization; Fluoroquinolones; Humans; Influenza, | 2010 |
[Levofloxacin and other fluoroquinolones in therapy of respiratory tract infections].
Topics: Administration, Oral; Anti-Bacterial Agents; Biological Availability; Fluoroquinolones; Humans; Levo | 2011 |
Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxaci | 2012 |
Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax.
Topics: Animals; Anthrax; Anthrax Vaccines; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antigens, Bacteri | 2012 |
[The use of levofloxacin for the empirical treatment of exacerbations of mild, chronic COPD: Is it justified in under-65-years-old patients with no comorbidity?].
Topics: Anti-Infective Agents; Humans; Levofloxacin; Ofloxacin; Pulmonary Disease, Chronic Obstructive; Resp | 2002 |
Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections.
Topics: Administration, Oral; Aged; Aged, 80 and over; Area Under Curve; Cohort Studies; Drug Administration | 2003 |
Fluoroquinolones in ambulatory ENT and respiratory tract infections: rarely appropriate.
Topics: Ambulatory Care; Ciprofloxacin; Contraindications; Fluoroquinolones; Humans; Ofloxacin; Otitis; Resp | 2003 |
[Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Cefdinir; Cephalosporins; Ciprof | 2002 |
[Epidemiological study on patients with pneumococcal respiratory tract infection in a Japanese health facility during the past year].
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Ceph | 2001 |
Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Azithromycin; Child; Child, Preschool; Drug Resistan | 2003 |
The influence of comorbidity on the effect of levofloxacin treatment success of ambulatory respiratory tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Child; Child, Preschool; Chlamydo | 2003 |
A 65-year-old woman with acute cough illness and an important engagement.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Antitussive Agents; Antiviral Age | 2003 |
Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer.
Topics: Adult; Aged; Anti-Infective Agents; Bacteria; Cellulose; Chromatography, High Pressure Liquid; Femal | 2003 |
The activity of levofloxacin and other antimicrobials against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999-2002.
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Global Health; Humans; Levofloxacin; Mi | 2003 |
[Antibiotics-resistance pattern and genetic type of Streptococcus pneumoniae isolated from children in Hangzhou].
Topics: Anti-Bacterial Agents; Cefotaxime; Child, Preschool; China; Chloramphenicol; Drug Resistance, Bacter | 2004 |
[Use of the antibacterial agent levofloxacin for acute upper respiratory tract infection accompanied by fever (> or = 38 degrees C)].
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Bacterial Agents; Body Temperature; Drug Administration | 2003 |
[Observational study investigating the use of levofloxacin in ICU patients].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Arrhythmias, Cardiac; B | 2004 |
Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections.
Topics: Abdominal Injuries; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bacteria, Aerobic; Fluoroqui | 2004 |
[Resistance surveillance of common community respiratory pathogens isolated in China, 2002 - 2003].
Topics: Anti-Bacterial Agents; Cefprozil; Cephalosporins; Child, Preschool; China; Community-Acquired Infect | 2004 |
Antimicrobial susceptibility to levofloxacin and other antibacterial agents among common respiratory pathogens-a Brazilian perspective from the GLOBAL Surveillance Initiative 2001-2002.
Topics: Anti-Bacterial Agents; Brazil; Drug Resistance, Bacterial; Haemophilus influenzae; Humans; Levofloxa | 2004 |
Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Community-Acquired Infections; Drug Resistance, Bacterial | 2004 |
Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Ha | 2005 |
Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; DNA, Bacterial; Drug Resistance, | 2005 |
Levofloxacin-induced acute fulminant hepatic failure in a patient with chronic hepatitis B infection.
Topics: Anti-Bacterial Agents; Fatal Outcome; Female; Hepatic Encephalopathy; Hepatitis B, Chronic; Humans; | 2005 |
Efficacy and safety in the oral treatment of purulent chest disease and pneumonia with cefixime, ofloxacin, and ciprofloxacin.
Topics: Administration, Oral; Anti-Bacterial Agents; Bronchitis; Cefixime; Ciprofloxacin; Clinical Trials as | 1989 |
Ofloxacin versus amoxicillin in the treatment of lower respiratory tract infections. A multicenter prospective clinical trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clinical Trials as Topic; Female; Humans; Male; Mid | 1989 |
Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event?
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Electrocardiography; F | 2006 |
Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Humans; Levofloxacin; Ofloxacin; Respiratory T | 2006 |
parE mutations in Streptococcus pneumoniae may reduce bactericidal activity of respiratory fluoroquinolones.
Topics: Anti-Bacterial Agents; Aza Compounds; DNA Topoisomerase IV; Fluoroquinolones; Humans; Microbial Sens | 2007 |
Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; DNA, Bacterial; Drug Resistance, Bacterial; Er | 2007 |
[Antibacterial activity of tosufloxacin against major organisms detected from patients with respiratory infections].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Fluoroquinolones; Haemophilus influenzae; Humans; Klebsiella p | 2007 |
In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactams; Drug Therapy, Combination; Humans; Levofloxacin; Meth | 2007 |
Recall urticaria related to levofloxacin.
Topics: Adult; Anti-Bacterial Agents; Female; Humans; Levofloxacin; Male; Ofloxacin; Respiratory Tract Infec | 2008 |
Hypoglycemia and levofloxacin: a case report.
Topics: Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemia; Levofloxacin; Ofloxacin; | 2008 |
Daily single-dose regimen and alternate-two-week triple-dose/day regimen of oral ofloxacin for the prophylaxis and control of exacerbations of chronic respiratory tract infections.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Chronic Disease; Drug Administration Schedule; | 1995 |
Pharmacokinetics of ofloxacin through three administration routes.
Topics: Administration, Oral; Adult; Biological Availability; Chromatography, High Pressure Liquid; Female; | 1994 |
North American (United States and Canada) comparative susceptibility of two fluoroquinolones: ofloxacin and ciprofloxacin. A 53-medical-center sample of spectra of activity. North American Ofloxacin Study Group.
Topics: Bacteria; Bacterial Infections; Canada; Ciprofloxacin; Enterobacteriaceae; Female; Genitalia; Humans | 1994 |
Effective monitoring of concentrations of ofloxacin in saliva of patients with chronic respiratory tract infections.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Female; Humans; Kidney Diseases; Male; Middle Aged; | 1994 |
Dangers of oral fluoroquinolone treatment in community acquired upper respiratory tract infections.
Topics: Administration, Oral; Adult; Aged; Ciprofloxacin; Community-Acquired Infections; Female; Humans; Mal | 1994 |
In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria | 1993 |
[Clinical analysis of ofloxacin in treatment of postinfectious exacerbations of endogenous bronchial asthma].
Topics: Adult; Aged; Asthma; Bronchoalveolar Lavage Fluid; Female; Humans; Leukocyte Count; Male; Middle Age | 1993 |
Criteria for use of ofloxacin and lomefloxacin in adult inpatients and outpatients.
Topics: Adult; Anti-Infective Agents; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Infectio | 1993 |
Levofloxacin in patients with severe respiratory tract infection.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Asthma; Bronchitis; Chronic Disease; Clarithromy | 1995 |
Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae: results of a 1992-93 western Europe and USA collaborative surveillance study. The Alexander Project Collaborative Group.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Ciprofloxacin; Community-Acquired Infections; Drug Re | 1996 |
[Ten-year experience with the use of ofloxacin in the treatment of wound infection].
Topics: Administration, Oral; Anti-Infective Agents; Bacteriuria; Drug Administration Schedule; Humans; Infu | 1996 |
In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacter | 1997 |
Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy.
Topics: Administration, Oral; Anti-Infective Agents; Biopsy; Bronchoscopy; Female; Fiber Optic Technology; H | 1997 |
[Occurrence of Moraxella catarrhalis in patients with respiratory tract infections].
Topics: Amoxicillin-Potassium Clavulanate Combination; Ampicillin Resistance; Drug Resistance, Microbial; Hu | 1997 |
Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; beta-Lactamases; Ceftriaxone; | 1997 |
In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Fluoroquinolones; Haemophilus Infections; Haemophi | 1998 |
A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Haemophilus influenzae; Humans; Le | 1998 |
Increase in quinolone resistance in a Haemophilus influenzae strain isolated from a patient with recurrent respiratory infections treated with ofloxacin.
Topics: Amino Acid Substitution; Anti-Infective Agents; DNA Topoisomerase IV; DNA Topoisomerases, Type II; F | 1999 |
[Levofloxacin-induced neurological adverse effects such as convulsion, involuntary movement (tremor, myoclonus and chorea like), visual hallucination in two elderly patients].
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Dyskinesia, Drug-Induced; Hallucinations | 1999 |
[Levofloxacin concentrations in serum, sputum and lung tissue: evaluation of its efficacy according to breakpoint].
Topics: Adult; Aged; Chronic Disease; Female; Humans; Levofloxacin; Lung; Male; Middle Aged; Ofloxacin; Pneu | 1999 |
Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation.
Topics: Animals; Biofilms; Chronic Disease; Clarithromycin; Disease Models, Animal; Drug Therapy, Combinatio | 2000 |
[Activities of antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Levofloxacin--Surveillance Group].
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gram-Negative Ba | 2000 |
[Treatment in general practice. Effective, well tolerated therapy].
Topics: Anti-Infective Agents; Bacterial Infections; Humans; Ofloxacin; Respiratory Tract Infections; Treatm | 2000 |
Comparative in vitro activity of telithromycin (HMR 3647), three macrolides, amoxycillin, cefdinir and levofloxacin against gram-positive clinical isolates in Japan.
Topics: Amoxicillin; Anti-Bacterial Agents; Cefdinir; Cephalosporins; Community-Acquired Infections; Drug Re | 2000 |
Effect of Mao-bushi-saishin-to on infection of ofloxacin resistant bacteria and of unknown origin.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Inflammatory Agents; Bacterial Infections; Body | 2000 |
Intravenous followed by oral ofloxacin in the treatment of community acquired lower respiratory tract infections in adults requiring hospitalisation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Community-A | 2000 |
[In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC].
Topics: Anti-Infective Agents; Bacteria; Dioxolanes; Drug Resistance, Microbial; Fluoroquinolones; Humans; L | 2000 |
[Comparative efficacy and safety of ciprofloxacin, ofloxacin, and pefloxacin in treatment of respiratory infections in children with cystic fibrosis].
Topics: Adolescent; Anti-Infective Agents; Arthritis; Child; Child, Preschool; Ciprofloxacin; Cystic Fibrosi | 2001 |
Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Community-Acquired Infections; Fluoro | 2001 |
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
Topics: Anti-Infective Agents; Canada; Drug Resistance, Bacterial; Drug Utilization; Hospitals; Humans; Levo | 2002 |
[Ofloxacin in the treatment of lower respiratory tract infections in patients with chronic pulmonary diseases].
Topics: Chronic Disease; Humans; Lung Diseases; Ofloxacin; Respiratory Tract Infections | 1992 |
[Clinical pharmacology and efficacy of levofloxacin in elderly patients].
Topics: Aged; Aged, 80 and over; Drug Evaluation; Female; Humans; Kidney Diseases; Levofloxacin; Male; Oflox | 1992 |
[Sputum penetration of levofloxacin and its clinical efficacy in patients with chronic lower respiratory tract infections].
Topics: Aged; Chronic Disease; Drug Evaluation; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; | 1992 |
[Laboratory and clinical studies on levofloxacin].
Topics: Adult; Aged; Bacteria; Drug Evaluation; Drug Resistance, Microbial; Female; Humans; Levofloxacin; Ma | 1992 |
Secretion of ofloxacin into saliva in patients with respiratory tract infection.
Topics: Administration, Oral; Aged; Aging; Female; Humans; Male; Middle Aged; Ofloxacin; Respiratory Tract I | 1992 |
A comparison of antimicrobial activity of ofloxacin, L-ofloxacin, and other oral agents for respiratory pathogens.
Topics: Administration, Oral; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Cefuroxime; Ciprof | 1992 |
Ofloxacin, a new broad-spectrum fluoroquinolone. Results from a Multicenter, National Comparative Activity Surveillance Study. The Ofloxacin Surveillance Group.
Topics: Anti-Infective Agents; Bacteria; Drug Resistance, Microbial; Enterobacteriaceae; Haemophilus influen | 1992 |
Activity of temafloxacin and other fluoroquinolones against typical and atypical community-acquired respiratory tract pathogens.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Fluoroquinolones; Humans; Microbial Sensitivity Test | 1991 |
In vitro activity of temafloxacin against gram-negative bacteria: an overview.
Topics: Anti-Infective Agents; Campylobacter; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Gram-Nega | 1991 |
In vivo evaluation of NM441, a new thiazeto-quinoline derivative.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dogs; Drug Evaluati | 1991 |
The use of quinolones in respiratory tract infections. Ofloxacin: current clinical aspects. Proceedings of the 17th International Congress of Chemotherapy. Berlin, Germany, June 24, 1991.
Topics: Humans; Ofloxacin; Respiratory Tract Infections | 1991 |
Activity of temafloxacin against respiratory pathogens.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Cells, Cultured; Ciprofloxacin; Dose-Response | 1991 |
Effects of ofloxacin on cell-mediated immune response and lymphokine production.
Topics: Analysis of Variance; Humans; Immunity, Cellular; Interferon Type I; Interferon-gamma; Interleukin-2 | 1990 |
[Ofloxacin in the treatment of infections of the respiratory tract in older patients].
Topics: Age Factors; Aged; Aged, 80 and over; Humans; Middle Aged; Ofloxacin; Respiratory Tract Infections; | 1990 |
Fatal vasculitis associated with ofloxacin.
Topics: Aged; Death, Sudden; Humans; IgA Vasculitis; Male; Ofloxacin; Respiratory Tract Infections | 1989 |
Clinical role of the quinolones today and in the future.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Clinical Protocols; Forecasting; Humans; | 1989 |
Clinical experience with ofloxacin (DL-8280) in the therapy of various infections.
Topics: Adolescent; Adult; Aged; Bacterial Infections; Child; Female; Gastroenteritis; Humans; Male; Middle | 1989 |
[A clinical experience of ofloxacin in patients with respiratory infection].
Topics: Adult; Aged; Drug Resistance, Microbial; Female; Humans; Male; Middle Aged; Ofloxacin; Respiratory T | 1989 |
Clinical use of the quinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; Diarrhea; Enoxacin; Gastrointestinal Diseases; Humans; Naphthy | 1987 |
[Gyrase inhibitor in pneumology. Ofloxacin--a new broad spectrum antibiotic in acute and chronic respiratory tract infections].
Topics: Adult; Aged; Anti-Infective Agents; Female; Humans; Male; Middle Aged; Ofloxacin; Oxazines; Respirat | 1985 |
[Clinical study on development of resistance of respiratory bacterial pathogens to ofloxacin and ciprofloxacin].
Topics: Adult; Bacteria; Child; Ciprofloxacin; Drug Resistance, Microbial; Female; Humans; Male; Microbial S | 1987 |
[In vitro activity of 3 fluoroquinolones on Branhamella catarrhalis].
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Humans; In Vitro Techniques; Microbial S | 1988 |
[Clinical experience with ofloxacin in the treatment of chronic respiratory tract disease aggravated by acute infection].
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Female; Haemophilus influenzae; Humans; Male; Middle | 1988 |
Efficacy of ofloxacin in the treatment of lower respiratory tract infections in general practice.
Topics: Adult; Aged; Aged, 80 and over; Family Practice; Female; Humans; Male; Middle Aged; Ofloxacin; Respi | 1988 |
Therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 in experimentally infected normal and alloxan-induced diabetic mice.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Diabetes Mellitus, Experimental; Female; Fluoroquinol | 1988 |
[Ofloxacin (RU 43280). Clinical study].
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Drug Therapy, Combination; Enterobacteriaceae Infect | 1987 |
[The role of ofloxacin (Tarivid) therapy in respiratory and urinary tract infections].
Topics: Acute Disease; Chronic Disease; Escherichia coli; Humans; Klebsiella; Ofloxacin; Proteus; Pseudomona | 1987 |
Clinical evaluation of ofloxacin in lower respiratory tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Chronic Disease; Female; Humans; | 1986 |
Ofloxacin in cystic fibrosis.
Topics: Adolescent; Adult; Anti-Infective Agents; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; | 1987 |
Ofloxacin in lower respiratory tract infections.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Female; Humans; Male; Middle Aged; Ofloxacin; Oxazin | 1987 |
Clinical efficacy of the new quinolones in lower respiratory infections.
Topics: Aged; Anti-Infective Agents; Bacteria; Ciprofloxacin; Enoxacin; Humans; Microbial Sensitivity Tests; | 1987 |
Comparative activity of ofloxacin with reference to bacterial strains isolated in in-patients and out-patients.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cross Infection; Dose-Response Relationship, | 1986 |